IBRX250117C12500
- 0.04
- 0.000.00%
ImmunityBio Newsroom
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Biggest Stock Movers Friday: JBHT, RIVN, and More
Why ImmunityBio, Inc. (IBRX) Is Skyrocketing
Sector Update: Health Care
ImmunityBio Shares Jump 18% After Cancer Pipeline, Drug Application Updates
ImmunityBio Provides Update On FDA Submissions For 2025
ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday
ImmunityBio Price Target Maintained With a $30.00/Share by D. Boral Capital
Express News | Immunitybio: To Submit Bla in 2025 for Second- & Third-Line Treatment of Patients With Nsclc Progressing on Checkpoint Inhibitors
Express News | Immunitybio: Preparing to Submit Sbla in 2025 for Nmibc Bcg Unresponsive Papillary Disease
Express News | Immunitybio Provides Regulatory Update on Global Submission for Anktiva + Bcg in Bcg Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in Europe and United Kingdom
Express News | Immunitybio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting With the Agency
Why ImmunityBio, Inc. (IBRX) Is the Top Small Cap Stock to Buy With the Highest Upside Potential
ImmunityBio Initiated at Buy by BTIG
BTIG Initiates ImmunityBio at Buy With $6 Price Target
BTIG Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $6
Express News | Immunitybio Announces Permanent J-Code (J9028) for Anktiva® Is Now Effective
ImmunityBio Analyst Ratings
Express News | D. Boral Capital Served as Co-Manager to Immunitybio, Inc. (Nasdaq: Ibrx) in Connection With Its $100.0 Million Underwritten Public Offering